HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $195

Benzinga Newsdesk www.benzinga.com Positive 84.4%

Neg 0% Neu 0% Pos 84.4%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $195.